SLC5A2 and neoplasm: Thus, it is conceivable that supplementing SGLT2 inhibitors with traditional chemotherapeutics might be beneficial in the treatment of cancer, where SGLT2 inhibitors can not only block the supply of glucose, the primary fuel for the tumor cells but also curtail sympathetic output.